Cover Image
市場調查報告書

細胞銀行的新趨勢

Emerging Trends in Cell Banking

出版商 Technical Insights (Frost & Sullivan) 商品編碼 322315
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞銀行的新趨勢 Emerging Trends in Cell Banking
出版日期: 2014年12月29日 內容資訊: 英文 60 Pages
簡介

本報告提供主細胞庫(MCB)及工作細胞庫(WCB)的新趨勢相關調查、技術的能力與價值鏈、市場成長的各種影響因素分析、技術引進及技術開發的評估及技術、產品與服務開發者的建議、專利、主要聯絡處的資料等彙整資料。

第1章 摘要整理

  • 調查範圍
  • 調查手法
  • 重要的調查結果

第2章 技術概要及趨勢

  • 技術概要
  • 技術流程概要
  • 技術價值鏈
  • 技術能力

第3章 影響評估及分析

  • 重要的技術創新對市場的影響
  • 技術對市場的影響

第4章 技術創新的普及需求評估

  • 技術的採用週期

第5章 機會的評估及路徑規劃

  • 方案模擬及新市場機會
  • 需求面分析
  • 生物醫藥品經營者為了維持自家公司的細胞株、開發新細胞株,擴大與CMO的合作
  • 企業簡介

第6章 主要聯絡處、專利、決策依據的資料庫

  • 主要的聯絡處
  • 專利
  • DSD(決策依據的資料庫):政府醫療費
  • DSD(決策依據的資料庫):醫藥品R&D支出和醫藥品市場上的比例
  • DSD(決策依據的資料庫):醫藥品R&D支出
  • DSD(決策依據的資料庫):整體醫療費
  • DSD(決策依據的資料庫):對生物科技R&D的創業投資投資額
  • 免責聲明

第7章 關於FROST & SULLIVAN

目錄
Product Code: D567-01-00-00-00

Trends in Master and Working Cell Baking

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of most operational challenges. Indeed, cultured cells are frequently used to generate monoclonal antibodies (MAbs), enzymes, or substrates to be then utilized in other types of tests, such as ligand binding and enzymatic assays, thereby requiring distinct characterization and control measures to guarantee functional reliability over time.

The extreme sensitivity of cellular components to different chemical and physical elements and the possibility of alterations in the proteome expression profiles hold significant importance in assessing biopharmaceutical products. Therefore, the need for homogeneous, stable cell banks capable of safeguarding starting cellular material is substantial to perform reliable cell-based assays. Master and working cell banks (MCBs and WCBs) are established with the aim to provide a continuous source of viable cells that allow to generate accurate results for specific test methods.

This research service brings out the emerging trends in MCBs and WCBs on a global scale, through a detailed description of:

  • The technology capability and value chain; analysis of global technology trends.
  • An impact analysis of major drivers, restraints, and challenges influencing the growth of cell banks by timeframes.
  • An assessment of technology adoption and development, by region, demand side analysis, and recommendations for technology/product/services developers.
  • An evaluation of scenario modelling and emerging opportunities in MCBs and WCBs, technology management strategies and technology application roadmap.
  • A list of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Research Scope
  • 2. Research Methodology
  • 3. Key Findings

2. TECHNOLOGY SNAPSHOT AND TRENDS

Technology Snapshot and Trends

  • 1. Technology Overview
  • 2. Technology Process Overview
  • 3. Technology Value Chain
  • 4. Technology Capability
  • 5. Technology Capability
  • 6. Technology Capability
  • 7. Technology Capability

3. IMPACT ASSESSMENT AND ANALYSIS

Impact Assessment and Analysis

  • 1. Market Impact of Key Innovations
  • 2. Market Impact of Key Innovations
  • 3. Market Impact of Technology
  • 4. Market Impact of Technology

4. DIFFUSION OF INNOVATIONS AND NEEDS ASSESSMENT

Diffusion of Innovations and Needs Assessment

  • 1. Technology Adoption Cycle
  • 2. Technology Adoption Cycle
  • 3. Technology Adoption Cycle
  • 4. Technology Adoption Cycle
  • 5. Technology Adoption Cycle
  • 6. Technology Adoption Cycle
  • 7. Technology Adoption Cycle
  • 8. Technology Adoption Cycle
  • 9. Technology Adoption Cycle
  • 10. Technology Adoption Cycle
  • 11. Technology Adoption Cycle

5. OPPORTUNITY EVALUATION AND ROADMAPPING

Opportunity Evaluation and Roadmapping

  • 1. Scenario Modelling and Emerging Opportunities
  • 2. Demand Side Analysis
  • 3. Demand Side Analysis
  • 4. Biophramas are increasing their partnerships with CMOs, for storing their proprietary cell lines and the development of novel cell lines.
  • 5. Company Profiles (continued)
  • 6. Company Profiles (continued)
  • 7. Company Profiles (continued)
  • 8. Company Profiles (continued)
  • 9. Company Profiles (continued)

6. KEY CONTACTS, KEY PATENTS, ANDDECISION SUPPORT DATABASE

Key Contacts, Key Patents, andDecision Support Database

  • 1. Key Contacts
  • 2. Key Contacts (continued)
  • 3. Key Contacts (continued)
  • 4. Key Contacts (continued)
  • 5. Patents
  • 6. Patents (continued)
  • 7. DSD-Government Healthcare Expenditure (Billion USD)
  • 8. DSD-Pharmaceutical R&D Expenditure as a Percentage of Pharmaceutical Market
  • 9. DSD-Pharmaceutical R&D Expenditure (Million USD)
  • 10. DSD-Total Healthcare Expenditure (Billion USD)
  • 11. DSD-Venture Capital Investment in Biotech R&D (Million USD)
  • 12. Legal Disclaimer

7. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. Who is Frost & Sullivan
  • 2. What Makes Us Unique
  • 3. TEAM Methodology
  • 4. Our Global Footprint 40+ Offices
Back to Top